• Retrospective• No data on steroid use, MGMT promoter methylation status, and IDH mutation status (patients diagnosed between 2005 and 2013)• ≈50% of patients had comorbidities with potential impact on NLR• No correlation of absolute neutrophil and lymphocyte counts with overall survival• Multivariate analysis adjusted for KPS, tumor location, first-line and second-line therapy, and presence of comorbidities. The gene discussed is MGMT; the disease is neoplasm.